Literature DB >> 29772431

Down-regulation of ETS2 inhibits the invasion and metastasis of renal cell carcinoma cells by inducing EMT via the PI3K/Akt signaling pathway.

Guang-Wei Zhang1, Xin Tian1, Yang Li1, Zhi-Qiang Wang1, Xiao-Dong Li1, Chao-Yang Zhu2.   

Abstract

V-ets erythroblastosis virus E26 oncogene homolog 2 (ETS2), belonging to the ETS family of transcription factors, is implicated in a broad range of cellular functions. Recently, ETS2 has been found playing an important role in the progression of some types of cancers. However, it remains unclear whether ETS2 has any effects on renal cell carcinoma (RCC). In this study, we investigated the biological functions of ETS2 in RCC. The results showed that ETS2 was highly expressed in RCC tissues and cell lines and its expression had an association with clinicopathological characteristics of RCC patients. In addition, down-regulation of ETS2 significantly inhibited RCC cell invasion in vitro and metastasis in vivo as well as suppressed the epithelial-mesenchymal transition (EMT) process. We also found that ETS2 down-regulation significantly reduced the levels of PI3K and Akt phosphorylation in RCC cells. Taken together, we suggest that ETS2 is of potential value as a molecular target for RCC treatment.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  ETS2; Epithelial-Mesenchymal transition (EMT); Invasion; Metastasis; Renal cell carcinoma (RCC)

Mesh:

Substances:

Year:  2018        PMID: 29772431     DOI: 10.1016/j.biopha.2018.05.029

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  8 in total

1.  ETS2 promotes epithelial-to-mesenchymal transition in renal fibrosis by targeting JUNB transcription.

Authors:  Fang Yao; Xiaojing Wang; Zhong-Kai Cui; Haibing Lan; Xiaolan Ai; Qiancheng Song; Zhenguo Chen; Jun Yang; Bingyi Wu; Xiaochun Bai
Journal:  Lab Invest       Date:  2019-10-22       Impact factor: 5.662

2.  CPA4 Promotes EMT in Pancreatic Cancer via Stimulating PI3K-AKT-mTOR Signaling.

Authors:  Qingliang Shao; Zhiqiang Zhang; Rongxian Cao; Hui Zang; Wanting Pei; Tian Sun
Journal:  Onco Targets Ther       Date:  2020-08-25       Impact factor: 4.147

3.  UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.

Authors:  Peng Hao; Bo Kang; Yapeng Li; Wenqi Hao; Feihong Ma
Journal:  Mol Med Rep       Date:  2019-06-03       Impact factor: 2.952

4.  Expression characterization and transcription regulation analysis of porcine Yip1 domain family member 3 gene.

Authors:  Dongjiao Ni; Xiang Huang; Zhibo Wang; Lin Deng; Li Zeng; Yiwei Zhang; Dongdong Lu; Xinhua Zou
Journal:  Asian-Australas J Anim Sci       Date:  2019-07-02       Impact factor: 2.509

5.  Integrated analysis of DNA methylation and mRNA expression profiles to identify key genes involved in the regrowth of clinically non-functioning pituitary adenoma.

Authors:  Sen Cheng; Chuzhong Li; Weiyan Xie; Yazhou Miao; Jing Guo; Jichao Wang; Yazhuo Zhang
Journal:  Aging (Albany NY)       Date:  2020-02-03       Impact factor: 5.682

6.  Prognostic and Predictive Value of Transcription Factors Panel for Digestive System Carcinoma.

Authors:  Guoxu Fang; Jianhui Fan; Zongren Ding; Rong Li; Kongying Lin; Jun Fu; Qizhen Huang; Yongyi Zeng; Jingfeng Liu
Journal:  Front Oncol       Date:  2021-10-21       Impact factor: 6.244

7.  Acylglycerol kinase promotes tumour growth and metastasis via activating the PI3K/AKT/GSK3β signalling pathway in renal cell carcinoma.

Authors:  Qian Zhu; Ai-Lin Zhong; Hao Hu; Jing-Jing Zhao; De-Sheng Weng; Yan Tang; Qiu-Zhong Pan; Zi-Qi Zhou; Meng-Jia Song; Jie-Ying Yang; Jun-Yi He; Yuan Liu; Min Li; Wan-Ming Hu; Chao-Pin Yang; Tong Xiang; Ming-Yuan Chen; Gang Ma; Ling Guo; Jian-Chuan Xia
Journal:  J Hematol Oncol       Date:  2020-01-03       Impact factor: 17.388

Review 8.  Role of PI3K/AKT pathway in cancer: the framework of malignant behavior.

Authors:  Ningni Jiang; Qijie Dai; Xiaorui Su; Jianjiang Fu; Xuancheng Feng; Juan Peng
Journal:  Mol Biol Rep       Date:  2020-04-24       Impact factor: 2.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.